Author

Jenna Bradley

AstraZeneca (United Kingdom)ORCID 0000-0002-0073-4245Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:clustering· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:metabolomics· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Abdel Wahad Bidar· 1 shared Alaa OthmaniD· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anna Schantz· 1 shared Babak Alaei-MahabadiiD· 1 shared Berend SnijderiD· 1 shared Camilla Johansson· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Abdel Wahad Bidar

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines

Sarah Cherkaoui, Stephan Durot, Jenna Bradley, Susan E. Critchlow, Sébastien Dubuis, Mauro Miguel Masiero, Rebekka Wegmann, Berend Snijder, Alaa Othman, Claus Bendtsen, Nicola Zamboni

The paper profiles the metabolome of 180 cancer cell lines and identifies two major metabolic types linked to epithelial-mesenchymal transition (EMT).

Molecular Systems Biology · Nov 1, 2022Peer-reviewedSystems Biology

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal, Frank Seeliger, Camilla Johansson, Abdel Wahad Bidar, Lukas Badertscher, Emma Jane Davies, Elizabeth L. Hardaker, Carla P. Martins, Therése Admyre, Amir Taheri‐Ghahfarokhi, Jenna Bradley, Anna Schantz, Babak Alaei-Mahabadi, , Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

bioRxiv · Apr 6, 2020 · PreprintGenomics